# A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

> **NCT02262741** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 71 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **BIOLOGICAL:** MEDI4736
- **BIOLOGICAL:** tremelimumab

## Key facts

- **NCT ID:** NCT02262741
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-15
- **Primary completion:** 2017-09-21
- **Final completion:** 2017-09-21
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2017-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262741, "A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02262741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*